A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
require the label of a drug to list the country of origin 
of each of the drug’s active ingredients. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘International Pharma-
4
ceutical Transparency Act of 2019’’. 
5
SEC. 2. COUNTRY-OF-ORIGIN LABELING FOR ACTIVE IN-
6
GREDIENTS IN DRUGS. 
7
(a) MISBRANDING.—Section 502 of the Federal 
8
Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amend-
9
ed by adding at the end the following: 
10
00:25 Dec 14, 2019
H5381
2 
•HR 5381 IH
‘‘(ee) If it is a drug and its label fails to list the coun-
1
try of origin of each of its active ingredients.’’. 
2
(b) APPLICABILITY.—Section 502(ee) of the Federal 
3
Food, Drug, and Cosmetic Act, as added by subsection 
4
(a), applies beginning on the day that is 6 months after 
5
the date of enactment of this Act. 
6
Æ 
00:25 Dec 14, 2019
H5381
